|Last Price$17.27||Day Change (%)0.12%|
|Open Price$17.27||Day Change ($)0.02|
|Day Range17.27–17.27||52-Week Range15.96–17.35|
As of Fri 03/24/2017 | USD
Verastem Reports Year-End 2016 Financial Results
Clovis Oncology Presents New Data from Phase 2 Studies of Rucaparib in Advanced Ovarian Cancer at 2017 SGO Annual Meeting on Women’s Cancer
Chi-Med Presented Sulfatinib Neuroendocrine Tumors Phase Ib/II Results at the 14th Annual Conference of European Neuroendocrine Tumor Society
ImmunoGen Presents Phase 1 Biopsy Expansion Cohort Data at the Society of Gynecologic Oncology Annual Meeting
Chi-Med Announces Positive Top-Line Results for FRESCO, its Phase III Pivotal Registration Trial of Fruquintinib in Patients with Locally Advanced or Metastatic Colorectal Cancer
UPDATE: Here's what financial advisers are most worried about in Trump era
A curious move, at a curious time, for purportedly, a curious reason, that is also a slap in the face to CPAs with the PFS credential.
This article represents opinions of the author and not those of his firm and are subject to change from time to time and do not constitute a recommendation to purchase and sale any security nor to engage in any particular investment strategy. The information contained here has been obtained from ...
Before investing you should carefully consider the Fund’s investment objectives, risks, charges and expenses. This and other information is in the prospectus. Please read the prospectus carefully before you invest. Foreside Fund Services, LLC, Distributor. An investment in the Funds is subject to ...
To the extent that this content includes references to securities, those references do not constitute an offer or solicitation to buy, sell or hold such security. AdvisorShares is a sponsor of actively managed exchange-traded funds (ETFs) and holds positions in all of its ETFs. This document should ...